Associations Between GLP-1 Receptor Agonists and Alopecia: A Multi-Center Retrospective Analysis and Public Interest Trends

    October 2025 in “ JEADV Clinical Practice ”
    Lauren Ching, Christopher A. Guirguis, Joe K. Tung
    Studysummary This study found that patients using GLP-1 receptor agonists, specifically liraglutide, dulaglutide, and semaglutide, had a higher likelihood of being diagnosed with androgenetic alopecia, while those on exenatide showed increased odds for both androgenetic alopecia and telogen effluvium.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 4

    1. Alopecia and Semaglutide: Connecting the Dots for Patient Safety Journal of Cosmetic Dermatology · 2025
    2. Glucagon-Like Peptide-1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study Journal of the American Academy of Dermatology · 2025
    3. Treatment of Insulin Resistance With Tirzepatide Leading to Improvement of Hair Loss JAAD Case Reports · 2024
    4. GLP-1 Agonists and Hair Loss: A Call for Further Investigation International Journal of Dermatology · 2024